Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Oreterra Receives Conditional Approval to Sell Option to Buy Down Newmont Lake Royalty to Enduro Metals
Harvest Gold Announces Non-Brokered Private Placement To Fund 2026 Drill Program On Its Flagship Mosseau Property